Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMetabolism, Transport, and Pharmacogenomics

The Molecular Mechanism of Intestinal Levodopa Absorption and Its Possible Implications for the Treatment of Parkinson’s Disease

Simone M. R. Camargo, Raphael N. Vuille-dit-Bille, Luca Mariotta, Tamara Ramadan, Katja Huggel, Dustin Singer, Oliver Götze and François Verrey
Journal of Pharmacology and Experimental Therapeutics October 2014, 351 (1) 114-123; DOI: https://doi.org/10.1124/jpet.114.216317
Simone M. R. Camargo
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphael N. Vuille-dit-Bille
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Mariotta
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamara Ramadan
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katja Huggel
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dustin Singer
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Götze
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Verrey
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland (S.M.R.C., R.N.V.-d.-B., L.M., T.R., K.H., D.S., F.V.); and Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland (O.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Levodopa (L-DOPA) is the naturally occurring precursor amino acid for dopamine and the main therapeutic agent for neurologic disorders due to dopamine depletion, such as Parkinson’s disease. l-DOPA absorption in small intestine has been suggested to be mediated by the large neutral amino acids transport machinery, but the identity of the involved transporters is unknown. Clinically, coadministration of l-DOPA and dietary amino acids is avoided to decrease competition for transport in intestine and at the blood-brain barrier. l-DOPA is routinely coadministered with levodopa metabolism inhibitors (dopa-decarboxylase and cathechol-O-methyl transferase inhibitors) that share structural similarity with levodopa. In this systematic study involving Xenopus laevis oocytes and Madin-Darby canine kidney epithelia expression systems and ex vivo preparations from wild-type and knockout mice, we identified the neutral and dibasic amino acids exchanger (antiporter) b0,+AT-rBAT (SLC7A9-SLC3A1) as the luminal intestinal l-DOPA transporter. The major luminal cotransporter (symporter) B0AT1 (SLC6A19) was not involved in levodopa transport. L-Leucine and L-arginine competed with levodopa across the luminal enterocyte membrane as expected for b0,+AT-rBAT substrates, whereas dopa-decarboxylase and cathechol-O-methyl transferase inhibitors had no effect. The presence of amino acids in the basolateral compartment mimicking the postprandial phase increased transepithelial levodopa transport by stimulating basolateral efflux via the antiporter LAT2-4F2 (SLC7A8-SLC3A2). Additionally, the aromatic amino acid uniporter TAT1 (SLC16A10) was shown to play a major role in l-DOPA efflux from intestinal enterocytes. These results identify the molecular mechanisms mediating small intestinal levodopa absorption and suggest strategies for optimization of delivery and absorption of this important prodrug.

Footnotes

    • Received May 6, 2014.
    • Accepted July 25, 2014.
  • S.M.R.C. and R.N.V.-d.-B. contributed equally to this work.

  • This work was supported by the Swiss National Foundation [Grant 31-130471/1 to F.V.].

  • dx.doi.org/10.1124/jpet.114.216317.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 351 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 351, Issue 1
1 Oct 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Molecular Mechanism of Intestinal Levodopa Absorption and Its Possible Implications for the Treatment of Parkinson’s Disease
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMetabolism, Transport, and Pharmacogenomics

Levodopa Transport in Intestine

Simone M. R. Camargo, Raphael N. Vuille-dit-Bille, Luca Mariotta, Tamara Ramadan, Katja Huggel, Dustin Singer, Oliver Götze and François Verrey
Journal of Pharmacology and Experimental Therapeutics October 1, 2014, 351 (1) 114-123; DOI: https://doi.org/10.1124/jpet.114.216317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleMetabolism, Transport, and Pharmacogenomics

Levodopa Transport in Intestine

Simone M. R. Camargo, Raphael N. Vuille-dit-Bille, Luca Mariotta, Tamara Ramadan, Katja Huggel, Dustin Singer, Oliver Götze and François Verrey
Journal of Pharmacology and Experimental Therapeutics October 1, 2014, 351 (1) 114-123; DOI: https://doi.org/10.1124/jpet.114.216317
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics